Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome: a double-blind controlled trial

Jill J. F. Belch, John K. Drury, Hilary Capell, Charles D. Forbes, Peter Newman, Fiona McKenzie, Paul Leiberman, Colin R. M. Prentice

    Research output: Contribution to journalArticlepeer-review

    121 Citations (Scopus)

    Abstract

    Two groups of outpatients (7 in each group) with Raynaud's syndrome, matched for severity of illness, were randomly allocated to receive at weekly intervals for three weeks either a 5 h intravenous infusion of buffer or epoprostenol (prostacyclin, PGI2) in buffer (7.5 ng/kg/min after the first hour). PGI2 reduced the frequency and duration of ischaemic attacks (both p less than 0.01). Hand temperature measurements with a thermocouple were significantly improved at 1 week; 6 weeks after the last infusion hand temperatures had returned to baseline. There was a corresponding loss of clinical response 8-10 weeks after the last infusion.
    Original languageEnglish
    Pages (from-to)313-315
    Number of pages3
    JournalLancet
    Volume1
    Issue number8320
    DOIs
    Publication statusPublished - 1983

    Fingerprint Dive into the research topics of 'Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome: a double-blind controlled trial'. Together they form a unique fingerprint.

    Cite this